Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
Open Access
- 16 March 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 102 (7), 1137-1144
- https://doi.org/10.1038/sj.bjc.6605612
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapyBritish Journal of Cancer, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal AntibodiesCancer Research, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingProceedings of the National Academy of Sciences of the United States of America, 2007
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBritish Journal of Cancer, 2007
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- The Hallmarks of CancerCell, 2000